Form 4: Xtant Medical Holdings Director, John K Bakewell, Reports Stock Award and Holdings

Director John K Bakewell reports acquisition of deferred stock units and holdings in Xtant Medical Holdings, Inc.

Summary

• On August 15, 2024, John K Bakewell, a director of Xtant Medical Holdings, Inc., reported transactions related to the company's common stock.
• Bakewell acquired 162,162 shares through a deferred stock unit award under the 2023 Equity Incentive Plan, vesting on August 15, 2025, contingent on continued service as a director.
• Following the reported transaction, Bakewell beneficially owns 755,888 shares of common stock, including 307,342 shares issuable upon settlement of deferred stock units granted under the 2023 Equity Incentive Plan.
• These deferred stock units also vest on future dates, conditioned upon Bakewell remaining a director.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard transaction. The director's acquisition of stock units is a positive sign, but it's a routine part of executive compensation.

Positives

• The director's continued holding of shares and acquisition of additional deferred stock units signals confidence in the company's future.
• The vesting conditions tied to continued service as a director align the director's interests with the long-term success of the company.

Future Outlook

The director's future stock ownership is tied to continued service, suggesting a commitment to the company's ongoing performance.

Industry Context

This filing is a routine disclosure related to insider transactions and is common for publicly traded companies. It provides transparency into the holdings and transactions of company insiders.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding the director's holdings and alignment with company performance.

Key Dates